Phase 1 Study of Oral PRT1419 in Patients with Relapsed/Refractory Hematologic Malignancies— PRT1419-01 (NCT04543305)
PRT1419 is designed to be a potent, selective, and orally available inhibitor of the anti-apoptotic protein, myeloid cell leukemia 1 (MCL1). MCL1 has been shown to have a critical role in promoting cancer cell survival and is frequently found to be amplified or overexpressed in both solid tumors and hematologic cancers.
This Phase 1 dose-escalation study of PRT1419 will seek to define the dosing schedule, maximally tolerated dose, and/or estimate the optimal biological dose to be used in subsequent development of PRT1419. The study will enroll patients with certain relapsed/refractory hematologic malignancies, including:
- High-risk myelodysplastic syndrome (MDS)
- Acute myeloid leukemia (AML)
- Chronic myelomonocytic leukemia (CMML)
- Non-Hodgkin’s lymphoma (NHL)
- Multiple myeloma (MM)